Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + cisplatin + pemetrexed + ramucirumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of platinum-based chemotherapy (carboplatin or cisplatin), pemetrexed (an antifolate agent), and ramucirumab (a VEGFR-2 inhibitor). It has been studied in clinical trials for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC), particularly non-squamous NSCLC. The combination works through multiple mechanisms: platinum agents disrupt DNA replication, pemetrexed inhibits folate-dependent enzymes, and ramucirumab blocks angiogenesis by targeting VEGFR-2.
02
Targets
TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)DHFR (Dihydrofolate reductase)DNAGART (GAR transformylase)
Beyond the preview
Go deeper on carboplatin + cisplatin + pemetrexed + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + cisplatin + pemetrexed + ramucirumab.